{"denoms":[{"counts":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"75"}],"units":"Participants"}],"groups":[{"description":"Estring 2mg ring inserted vaginally once every 12 weeks","id":"BG000","title":"Estring"},{"description":"Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment","id":"BG001","title":"Testosterone Cream"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"37","upperLimit":"78","value":"56"},{"groupId":"BG001","lowerLimit":"38","upperLimit":"74","value":"57"},{"groupId":"BG002","lowerLimit":"37","upperLimit":"78","value":"56"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"75"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"75"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Baseline Characteristics for 75 participants who initiated treatment. One participant consented and was assigned to ESTRING, but did not insert ESTRING prior to withdrawing from the study."}